| 1 |
Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial
Louis Fehrenbacher, Alexander I. Spira, Marcus D. Ballinger et al. · The Lancet
|
9 Mar 2016 |
2,823 |
| 2 |
Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA
M.C. Liu et al. · Annals of Oncology
Open access159 authors |
30 Mar 2020 |
1,567 |
| 3 |
Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set
Eric A. Klein, Donald Richards, Allen Lee Cohn et al. · Annals of Oncology
Open access |
24 Jun 2021 |
1,027 |
| 4 |
Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study
Ian W. Flinn, Richard van der Jagt, Brad S. Kahl et al. · Blood
Open access |
4 Mar 2014 |
646 |
| 5 |
Boundary spanning at the science–policy interface: the practitioners’ perspectives
ANGELA T. BEDNAREK, Carina A. Wyborn, Christopher Cvitanovic et al. · Sustainability Science
Open access |
27 Mar 2018 |
342 |
| 6 |
Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS)
Franck Morschhauser et al. · The Lancet Haematology
Open access |
29 Mar 2019 |
251 |
| 7 |
An open-label phase 2 trial of entospletinib (GS-9973), a selective spleen tyrosine kinase inhibitor, in chronic lymphocytic leukemia
Jeff Porter Sharman, Michael Hawkins, Kathryn S. Kolibaba et al. · Blood
Open access |
19 Feb 2015 |
186 |
| 8 |
Umbralisib, a Dual PI3Kδ/CK1ε Inhibitor in Patients With Relapsed or Refractory Indolent Lymphoma
Nathan Hale Fowler et al. · Journal of Clinical Oncology
Open access |
8 Mar 2021 |
163 |
| 9 |
FAIRLANE, a double-blind placebo-controlled randomized phase II trial of neoadjuvant ipatasertib plus paclitaxel for early triple-negative breast cancer
Mafalda Oliveira, Cristina Saura, Paolo Giovanni Nuciforo et al. · Annals of Oncology
Open access |
25 May 2019 |
157 |
| 10 |
Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of moderately emetogenic chemotherapy or anthracycline and cyclophosphamide regimens in patients with cancer: a randomised, active-controlled, double-blind, phase 3 trial
Lee Steven Schwartzberg, Manuel Modiano, Bernardo Leon Rapoport et al. · The Lancet Oncology
|
10 Aug 2015 |
154 |
| 11 |
Galunisertib plus neoadjuvant chemoradiotherapy in patients with locally advanced rectal cancer: a single-arm, phase 2 trial
Tomoko Yamazaki et al. · The Lancet Oncology
|
8 Aug 2022 |
147 |
| 12 |
Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of cisplatin-based highly emetogenic chemotherapy in patients with cancer: two randomised, active-controlled, double-blind, phase 3 trials
Bernardo Leon Rapoport, Martin Robert Chasen, Cesare Gridelli et al. · The Lancet Oncology
|
10 Aug 2015 |
142 |
| 13 |
Polatuzumab vedotin in combination with immunochemotherapy in patients with previously untreated diffuse large B-cell lymphoma: an open-label, non-randomised, phase 1b–2 study
Hervé Tilly, Franck Morschhauser, Nancy L. Bartlett et al. · The Lancet Oncology
Open access |
14 May 2019 |
140 |
| 14 |
Regorafenib plus nivolumab in patients with mismatch repair-proficient/microsatellite stable metastatic colorectal cancer: a single-arm, open-label, multicentre phase 2 study
Marwan Fakih et al. · EClinicalMedicine
Open access |
Apr 2023 |
114 |
| 15 |
Safety and Efficacy of Nivolumab in Patients With Advanced Non–Clear Cell Renal Cell Carcinoma: Results From the Phase IIIb/IV CheckMate 374 Study
Nicholas J. Vogelzang et al. · Clinical Genitourinary Cancer
Open access |
16 May 2020 |
107 |
| 16 |
Durable responses and reversible toxicity of high-dose interleukin-2 treatment of melanoma and renal cancer in a Community Hospital Biotherapy Program
Roxanne Payne, Lyn A. Glenn, Helena Maria Hoen et al. · Journal for ImmunoTherapy of Cancer
Open access |
2014 |
104 |
| 17 |
Prepectoral Revision Breast Reconstruction for Treatment of Implant-Associated Animation Deformity: A Review of 102 Reconstructions
Allen Gabriel, Steven R. Sigalove, Noemi M. Sigalove et al. · Aesthetic Surgery Journal
|
20 Jan 2018 |
92 |
| 18 |
RO-ILS: Radiation Oncology Incident Learning System: A report from the first year of experience
David J. Hoopes, Adam Paul Dicker, Nadine L. Eads et al. · Practical Radiation Oncology
|
25 Jun 2015 |
90 |
| 19 |
A first-in-human phase 1 study of a hepcidin monoclonal antibody, LY2787106, in cancer-associated anemia
Saroj Vadhan‐Raj, Rafat Abonour, Jonathan Wade Goldman et al. · Journal of Hematology & Oncology
Open access |
21 Mar 2017 |
89 |
| 20 |
Prepectoral Implant-Based Breast Reconstruction and Postmastectomy Radiotherapy: Short-Term Outcomes
Steven R. Sigalove, G. Patrick Maxwell, Noemi M. Sigalove et al. · Plastic & Reconstructive Surgery Global Open
Open access |
Dec 2017 |
82 |
| 21 |
A randomized, phase 2 trial of docetaxel with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic head and neck squamous cell cancer
Antonio Jimeno, Julie E. Bauman, Charles Weissman et al. · Oral Oncology
Open access |
13 Jan 2015 |
79 |
| 22 |
Significant clinical response to JAK1/2 inhibition in a patient with CSF3R-T618I-positive atypical chronic myeloid leukemia
Kim-Hien T. Dao, Magdolna Solti, Julia E. Maxson et al. · Leukemia Research Reports
Open access |
2014 |
76 |
| 23 |
Modified FOLFOX6 plus bevacizumab with and without nivolumab for first-line treatment of metastatic colorectal cancer: phase 2 results from the CheckMate 9X8 randomized clinical trial
Heinz‐Josef Lenz, Aparna R. Parikh, David Robert Spigel et al. · Journal for ImmunoTherapy of Cancer
Open access |
Mar 2024 |
74 |
| 24 |
Efficacy of the neurokinin‐1 receptor antagonist rolapitant in preventing nausea and vomiting in patients receiving carboplatin‐based chemotherapy
Paul Joseph Hesketh, Ian D. Schnadig, Lee Steven Schwartzberg et al. · Cancer
Open access |
13 May 2016 |
71 |
| 25 |
Antitumor activity and safety of combination therapy with the Toll-like receptor 9 agonist IMO-2055, erlotinib, and bevacizumab in advanced or metastatic non-small cell lung cancer patients who have progressed following chemotherapy
David A. B. Smith, Paul Conkling, Donald Richards et al. · Cancer Immunology Immunotherapy
Open access |
26 Apr 2014 |
69 |
| 26 |
The Impact of Closed Incision Negative Pressure Therapy on Postoperative Breast Reconstruction Outcomes
Allen Gabriel, Steven R. Sigalove, Noemi M. Sigalove et al. · Plastic & Reconstructive Surgery Global Open
Open access |
Aug 2018 |
67 |
| 27 |
Impact of whole systems traditional Chinese medicine on in-vitro fertilization outcomes
Lee Hullender Rubin, Michael S. Opsahl, Klaus E. Wiemer et al. · Reproductive BioMedicine Online
Open access |
24 Feb 2015 |
66 |
| 28 |
Ublituximab ( TG ‐1101), a novel glycoengineered anti‐ CD 20 antibody, in combination with ibrutinib is safe and highly active in patients with relapsed and/or refractory chronic lymphocytic leukaemia: results of a phase 2 trial
Jeff Porter Sharman, Charles Michael Farber, Daruka Mahadevan et al. · British Journal of Haematology
Open access |
16 Dec 2016 |
62 |
| 29 |
Recruitment and Retention of Families in Clinical Trials with Longitudinal Designs
Sandra Adams Motzer, Jean Reynolds Moseley, Frances Marcus Lewis · Western Journal of Nursing Research
|
Jun 1997 |
56 |
| 30 |
Functional Mapping of AKT Signaling and Biomarkers of Response from the FAIRLANE Trial of Neoadjuvant Ipatasertib plus Paclitaxel for Triple-Negative Breast Cancer
Zhen Shi, Julia Dianne Wulfkuhle, Małgorzata Nowicka et al. · Clinical Cancer Research
Open access |
13 Dec 2021 |
55 |
| 31 |
Histologic and Clinical Changes in Vulvovaginal Tissue After Treatment With a Transcutaneous Temperature-Controlled Radiofrequency Device
Monique J. Vanaman Wilson, Joanna Bolton, Isabela T. Jones et al. · Dermatologic Surgery
|
17 Jan 2018 |
55 |
| 32 |
Umbralisib Plus Ublituximab (U2) Is Superior to Obinutuzumab Plus Chlorambucil (O+Chl) in Patients with Treatment Naïve (TN) and Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): Results from the Phase 3 Unity-CLL Study
John G. Gribben et al. · Blood
|
5 Nov 2020 |
54 |
| 33 |
Robotic surgical staging for obese patients with endometrial cancer
Karen Y. Tang, Stuart K. Gardiner, Claire H. Gould et al. · American Journal of Obstetrics and Gynecology
|
12 Jan 2012 |
52 |
| 34 |
Ublituximab plus ibrutinib versus ibrutinib alone for patients with relapsed or refractory high-risk chronic lymphocytic leukaemia (GENUINE): a phase 3, multicentre, open-label, randomised trial
Jeff Porter Sharman, Danielle M. Brander, Anthony R. Mato et al. · The Lancet Haematology
|
23 Feb 2021 |
50 |
| 35 |
Efficacy and safety of rolapitant for prevention of chemotherapy-induced nausea and vomiting over multiple cycles of moderately or highly emetogenic chemotherapy
Bernardo Leon Rapoport, Lee Steven Schwartzberg, Martin Robert Chasen et al. · European Journal of Cancer
Open access |
4 Feb 2016 |
48 |
| 36 |
Sequencing of Cabazitaxel and Abiraterone Acetate After Docetaxel in Metastatic Castration-Resistant Prostate Cancer: Treatment Patterns and Clinical Outcomes in Multicenter Community-Based US Oncology Practices
Guru Sonpavde, Menaka Bhor, Daniel Hennessy et al. · Clinical Genitourinary Cancer
Open access |
9 Jan 2015 |
48 |
| 37 |
An open‐label phase 2 trial of entospletinib in indolent non‐Hodgkin lymphoma and mantle cell lymphoma
David Jacob Andorsky, Kathryn S. Kolibaba, Sarit E. Assouline et al. · British Journal of Haematology
Open access |
5 Sep 2018 |
47 |
| 38 |
Frequently asked questions on surrogate endpoints in oncology-opportunities, pitfalls, and the way forward
Abhenil Mittal, Myung Sun Kim, S. Terence Dunn et al. · EClinicalMedicine
Open access |
13 Sep 2024 |
46 |
| 39 |
Plasma cell-free DNA (cfDNA) assays for early multi-cancer detection: The circulating cell-free genome atlas (CCGA) study
M.C. Liu, Eric A. Klein, Earl A. Hubbell et al. · Annals of Oncology
Open access |
Oct 2018 |
46 |
| 40 |
Neoadjuvant Talazoparib in Patients With Germline BRCA1/2 Mutation-Positive, Early-Stage Triple-Negative Breast Cancer: Results of a Phase II Study
Jennifer Keating Litton, Joseph Thaddeus Beck, Jason Michael Jones et al. · The Oncologist
Open access |
15 Jun 2023 |
45 |
| 41 |
TheraSphere Yttrium-90 Glass Microspheres Combined With Chemotherapy Versus Chemotherapy Alone in Second-Line Treatment of Patients With Metastatic Colorectal Carcinoma of the Liver: Protocol for the EPOCH Phase 3 Randomized Clinical Trial
Nikhil Chauhan, Mary F. Mulcahy, Riad Salem et al. · JMIR Research Protocols
Open access |
17 Jan 2019 |
44 |
| 42 |
The Safety of Bridging Radiation with Anti-BCMA CAR T-Cell Therapy for Multiple Myeloma
Shwetha H. Manjunath, Adam D. Cohen, Simon Francis Lacey et al. · Clinical Cancer Research
Open access |
15 Sep 2021 |
43 |
| 43 |
Treatment of CD30-positive systemic mastocytosis with brentuximab vedotin
Uma Borate, Amitkumar Mehta, Vishnu Reddy et al. · Leukemia Research
Open access |
28 Feb 2016 |
41 |
| 44 |
Intra-Arterial TheraSphere Yttrium-90 Glass Microspheres in the Treatment of Patients With Unresectable Hepatocellular Carcinoma: Protocol for the STOP-HCC Phase 3 Randomized Controlled Trial
Nikhil Chauhan, Janet Bukovcan, Éveline Boucher et al. · JMIR Research Protocols
Open access |
9 Jul 2018 |
40 |
| 45 |
Randomized Phase 2 Open-Label Study of R-CHOP ± Bortezomib in Patients (Pts) with Untreated Non-Germinal Center B-Cell-like (Non-GCB) Subtype Diffuse Large Cell Lymphoma (DLBCL): Results from the Pyramid Trial (NCT00931918)
John Paul Leonard, Kathryn S. Kolibaba, James Andrew Reeves et al. · Blood
|
3 Dec 2015 |
38 |
| 46 |
Psoriasiform eruptions during Kawasaki disease (KD): A distinct phenotype
Ellen S. Haddock, Antoanella Calame, Chisato Shimizu et al. · Journal of the American Academy of Dermatology
Open access |
5 Mar 2016 |
35 |
| 47 |
Safety and Efficacy of Nivolumab in Patients With Advanced Clear Cell Renal Cell Carcinoma: Results From the Phase IIIb/IV CheckMate 374 Study
Joshua Jemison McFarlane, Mark D. Kochenderfer, Mark R. Olsen et al. · Clinical Genitourinary Cancer
Open access |
14 Jun 2020 |
33 |
| 48 |
Randomised phase II trial of gemcitabine and nab-paclitaxel with necuparanib or placebo in untreated metastatic pancreas ductal adenocarcinoma
Eileen Mary O'Reilly, Diletta Barone, Devalingam Mahalingam et al. · European Journal of Cancer
Open access |
27 Apr 2020 |
33 |
| 49 |
Continuing routine cardiac surveillance in long-term use of pegylated liposomal doxorubicin: Is it necessary?
Sarah E. Gill, Kari Savage, Weiya Zhang Wysham et al. · Gynecologic Oncology
|
21 Mar 2013 |
33 |
| 50 |
Bintrafusp alfa (M7824), a bifunctional fusion protein targeting TGF-β and PD-L1: results from a phase I expansion cohort in patients with recurrent glioblastoma
Mustafa Khasraw, Michael Weller, David Lorente et al. · Neuro-Oncology Advances
Open access |
2021 |
29 |